Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

CHINA BIOTECH SERVICES HOLDINGS LIMITED
中國生物科技服務控股有限公司

(Incorporated in the Cayman Islands and continued in Bermuda with limited liability)

(Stock code: 8037)

ALTERATIONS IN TERMS OF CONVERTIBLE BONDS IN RELATION TO ADDITIONAL GUARANTEES

Reference is made to the announcements of China Biotech Services Holdings Limited dated 17 December 2024 and 27 December 2024 in relation to the issue of convertible bonds under general mandate. Unless the context otherwise requires, terms defined in the said announcements shall have the same meaning when used in this announcement.

As at the date of this announcement, none of the Convertible Bonds has been converted into Conversion Shares and the principal amount of the outstanding Convertible Bonds is US$6,000,000, which is repayable in full on 27 December 2026.

ADDITIONAL GUARANTEES

On 26 September 2025, the Company and the Subscriber entered into an amendment agreement to make certain amendments to the terms and conditions of the Convertible Bonds (the "**Alterations**"), whereby apart from the corporate guarantee provided by 鵬博(海南)硼中子醫療科技有限公司 (in English, for identification purpose only, Pengbo (Hainan) Medical Technology Co., Ltd.), the Convertible Bonds shall be secured by two additional guarantees in favour of the Subscriber including (i) a corporate guarantee provided by Genius Lead Limited (a controlling shareholder of the Company indirectly wholly-owned by Mr. Liu) (the "**Parent Corporate Guarantee**"); and (ii) an individual guarantee provided by Mr. Liu (the "**Individual Guarantee**", together with the Parent Corporate Guarantee, the "**Additional Guarantees**"). The Individual Guarantee also includes warranties and undertakings by Mr. Liu that he shall at all times be a Director and the chairman of the Board and, unless otherwise agreed in writing by the Subscriber, shall hold not less than 40% beneficial interest directly or indirectly in the Company.

Save for the aforesaid and certain consequential amendments to the terms and conditions of the Convertible Bonds arising from the addition of guarantors, all other principal terms of the Convertible Bonds shall remain unchanged.

The Alterations have taken effect on 26 September 2025.

GEM LISTING RULES IMPLICATIONS

As the Alterations do not take effect automatically under the terms and conditions of the Convertible Bonds, the Company has made an application to the Stock Exchange for, and the Stock Exchange has granted, approval of the Alterations pursuant to Rule 34.05 of the GEM Listing Rules.

As (i) Genius Lead Limited is a controlling shareholder of the Company and (ii) Mr. Liu is a Director and a controlling shareholder of the Company, they are both connected persons of the Company. Their provision of the Additional Guarantees therefore constitutes financial assistance received by the Group from connected persons and hence connected transactions under Chapter 20 of the GEM Listing Rules.

The Directors consider that such connected transactions are conducted on normal commercial terms or better as no guarantee fee or other consideration will be paid by the Group to Genius Lead Limited and Mr. Liu for their provision of the Additional Guarantees. Besides, the Additional Guarantees are not secured by the assets of the Group. Accordingly, their provision of the Additional Guarantees is fully exempt under Rule 20.88 of the GEM Listing Rules.

By order of the Board
China Biotech Services Holdings Limited
Chairman and Executive Director
Liu Xiaolin

Hong Kong, 29 September 2025

As at the date of this announcement, the Board comprises four executive Directors, namely Mr. Liu Xiaolin (Chairman), Mr. He Xun, Mr. Huang Song and Dr. Yin Ye; and three independent non-executive Directors, namely Mr. Yan Guoxiang, Dr. Guo Yuantao and Dr. Zhang Xiao.

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the "Latest Listed Company Information" page of the website of the Stock Exchange at www.hkexnews.hk for at least 7 days from the date of its publication and on the website of the Company at www.cbshhk.com.